Ballentine Partners, LLC Argenx Se Transaction History
Ballentine Partners, LLC
- $7.1 Billion
- Q3 2025
A detailed history of Ballentine Partners, LLC transactions in Argenx Se stock. As of the latest transaction made, Ballentine Partners, LLC holds 495 shares of ARGX stock, worth $449,450. This represents 0.01% of its overall portfolio holdings.
Number of Shares
495
Previous 558
11.29%
Holding current value
$449,450
Previous $307,000
18.89%
% of portfolio
0.01%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ARGX
# of Institutions
526Shares Held
26MCall Options Held
589KPut Options Held
320K-
Price T Rowe Associates Inc Baltimore, MD3.64MShares$3.31 Billion0.29% of portfolio
-
Janus Henderson Group PLC London, X02.58MShares$2.34 Billion0.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI2.19MShares$1.99 Billion2.46% of portfolio
-
Capital World Investors Los Angeles, CA1.96MShares$1.78 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY1.01MShares$918 Million0.01% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $50.2B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...